# A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

> **NCT05342636** · PHASE1,PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 90 (actual)

## Conditions studied

- Esophageal Squamous Cell Carcinoma (ESCC)

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** Coformulation favezelimab/pembrolizumab
- **BIOLOGICAL:** MK-4830
- **DRUG:** Lenvatinib
- **DRUG:** Irinotecan
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT05342636
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-27
- **Primary completion:** 2025-12-05
- **Final completion:** 2025-12-05
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05342636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05342636, "A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05342636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*